A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Completed · Phase 1

Conditions studied: Small Cell Lung Carcinoma

In brief

The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).

Key facts

Study ID

NCT00927875

Run by

Bristol-Myers Squibb

People needed

5

Starts

2010-02-01

Expected to finish

2012-09-01

Last updated by the study team

2013-06-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed small cell lung cancer, without prior chemotherapy treatment
• Men and Women at least 18 years old
• Eastern Cooperative Oncology Group (ECOG) status 0-2

You may not qualify if…

• Significant cardiovascular disease
• Prior treatment of small cell lung cancer is not permitted, except for palliative radiation to a limited field excluding the chest (e.g. for painful metastasis).
• Symptomatic brain metastases
• Women pregnant or breastfeeding
• Women of childbearing potential (WOCBP) unwilling/unable to use acceptable method to avoid pregnancy
• Uncontrolled medical disorder or active infection
• Concurrent therapy with any other investigational product

Where it is running

• Karmanos Cancer Institute — Detroit, Michigan, United States
• Local Institution — East Bentleigh, Victoria, Australia
• Local Institution — Edmonton, Alberta, Canada
• Local Institution — Ottawa, Ontario, Canada
• Local Institution — Villejuif, France
• Local Institution — Dublin, Dublin, Ireland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.